These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034 [TBL] [Abstract][Full Text] [Related]
72. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4. Blaney JE; Sathe NS; Goddard L; Hanson CT; Romero TA; Hanley KA; Murphy BR; Whitehead SS Vaccine; 2008 Feb; 26(6):817-28. PubMed ID: 18191005 [TBL] [Abstract][Full Text] [Related]
73. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4. Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041 [TBL] [Abstract][Full Text] [Related]
74. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822 [TBL] [Abstract][Full Text] [Related]
75. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Putnak R; Fuller J; VanderZanden L; Innis BL; Vaughn DW Am J Trop Med Hyg; 2003 Apr; 68(4):469-76. PubMed ID: 12875299 [TBL] [Abstract][Full Text] [Related]
76. Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys. Yoshimura M; Shinmura Y; Shishido T; Takagi S; Kameyama K; Sonoda K; Yoksan S; Kimachi K Vaccine; 2021 May; 39(23):3169-3178. PubMed ID: 33941407 [TBL] [Abstract][Full Text] [Related]
77. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Khanam S; Pilankatta R; Khanna N; Swaminathan S Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609 [TBL] [Abstract][Full Text] [Related]
78. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Durbin AP; McArthur J; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS Hum Vaccin; 2006; 2(4):167-73. PubMed ID: 17012875 [TBL] [Abstract][Full Text] [Related]
79. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice. Muné M; Rodríguez R; Ramírez R; Soto Y; Sierra B; Rodríguez Roche R; Marquez G; Garcia J; Guillén G; Guzmán MG Arch Virol; 2003 Nov; 148(11):2267-73. PubMed ID: 14579183 [TBL] [Abstract][Full Text] [Related]
80. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Blaney JE; Manipon GG; Firestone CY; Johnson DH; Hanson CT; Murphy BR; Whitehead SS Vaccine; 2003 Oct; 21(27-30):4317-27. PubMed ID: 14505914 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]